NDA 211358 · Vertex Pharms INC
Orkambi
Ivacaftor, Lumacaftor · Oral · Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Breakthrough therapyPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Aug 7, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
136
60 Phase 3, 11 recruiting
FAERS reports
8,538
5,384 serious, 158 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 24, 2026.
ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. ORKAMBI is a combination of ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, and lumacaftor, indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. ( 1 ) Limitations of Use: The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation. ( 1 ) Limitations of Use The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation .
Mechanism: The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. The F508del mutation results in protein misfolding, causing a defect in cellular processing and trafficking that targets the protein for degradation and therefore reduces the quantity of CFTR at the cell surface. The small amount of F508del-CFTR that reaches the cell surface is less stable and has low channel-open probability (defective gating activity) compared to wild-type CFTR protein. Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and...
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 13, 2024 Supplement 6 · Efficacy · priority review OrphanLabelLetterLetter
- Sep 2, 2022 Supplement 4 · Efficacy · priority review OrphanLetterLabel
- Aug 7, 2018 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyOrphanLabelLetterReview
3 products under this application
- ORKAMBI · IVACAFTOR 188MG/PACKET; LUMACAFTOR 150MG/PACKET · GRANULE, ORAL · Prescription
- ORKAMBI · IVACAFTOR 94MG/PACKET; LUMACAFTOR 75MG/PACKET · GRANULE, ORAL · Prescription
- ORKAMBI · IVACAFTOR 125MG/PACKET; LUMACAFTOR 100MG/PACKET · GRANULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ivacaftor" as an intervention, any sponsor and status, largest first.
- A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic FibrosisPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01931839 · 1,164 participants · Start Oct 2013 · Primary completion Apr 2016
Drug: Lumacaftor Plus Ivacaftor Combination; Ivacaftor · For: Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 166 sites in all
- A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT02565914 · 1,131 participants · Start Aug 2015 · Primary completion May 2019
Drug: TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 154 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05076149 · 597 participants · Start Oct 27, 2021 · Primary completion May 18, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 170 sites in all
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01807949 · 563 participants · Start Apr 2013 · Primary completion Apr 2014
Drug: Placebo; Lumacaftor Plus Ivacaftor Combination and 1 more · For: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Sites: Oakland, California; Sacramento, California; Aurora, Colorado · 82 sites in all
- A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR MutationPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT01807923 · 559 participants · Start May 2013 · Primary completion Apr 2014
Drug: Lumacaftor Plus Ivacaftor Combination; Ivacaftor and 1 more · For: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 89 sites in all
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With IvacaftorPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT02347657 · 510 participants · Start Jan 2015 · Primary completion Jan 20, 2017
Drug: VX-661 Plus Ivacaftor Combination; Ivacaftor and 2 more · For: Cystic Fibrosis
Sites: Little Rock, Arkansas; Long Beach, California; Denver, Colorado · 74 sites in all
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03525574 · 507 participants · Start Oct 9, 2018 · Primary completion Jan 9, 2023
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Tucson, Arizona; Little Rock, Arkansas; Long Beach, California · 110 sites in all
- A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination TherapyPivotal-lookingTerminated
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03447262 · 484 participants · Start Jul 13, 2018 · Primary completion Sep 9, 2020
Drug: VX-659/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Palo Alto, California; Aurora, Colorado · 100 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infective pulmonary exacerbation of cystic fibrosis1,462
- hospitalisation888
- dyspnoea559
- pulmonary function test decreased397
- cough395
- infection370
- chest discomfort344
- cystic fibrosis328
- pneumonia269
- malaise225
- nasopharyngitis202
- fatigue200
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 613 |
| 2016 | 1,493 |
| 2017 | 1,499 |
| 2018 | 1,638 |
| 2019 | 1,989 |
| 2020 | 728 |
| 2021 | 169 |
| 2022 | 121 |
| 2023 | 120 |
| 2024 | 69 |
| 2025 | 47 |
| 2026 | 52 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Orkambi (Lumacaftor/IVacaftor)
2024 spending
$634K
Beneficiaries
n/a
28 claims
Per beneficiary
n/a
$202.15 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,778,194 |
| 2021 | $1,483,307 |
| 2022 | $1,433,409 |
| 2023 | $1,094,041 |
| 2024 | $633,932 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG, Mall MA, Devínek P, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
Barry PJ, Mall MA, Álvarez A, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Keating C, Yonker LM, Vermeulen F, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM, McKone EF, Downey DG, et al. · Lancet 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
Ramsey BW, Davies J, McElvaney NG, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Multicenter Study
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.
Edwards SJ, Farrar BG, Ennis K, et al. · Health Technol Assess 2025 · Network Meta-Analysis, Systematic Review
Sponsor: Vertex Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.